Skip to content 
The fund employs a passive management - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials. more
| Time Frame | SBIO | S&P500 |
|---|---|---|
| 1-Week Return | -0.18% | 1.47% |
| 1-Month Return | -1.87% | 6.9% |
| 3-Month Return | 9.35% | 8.67% |
| 6-Month Return | 19.53% | 10.45% |
| 1-Year Return | 102.34% | 26.35% |
| 3-Year Return | 69.88% | 79.84% |
| 5-Year Return | 21.39% | 78.2% |
| 10-Year Return | 143.1% | 259.86% |
| Stock name | Ticker | Weight |
|---|---|---|
 Kymera Therapeutics Inc. | KYMR | 4.2% |
 Mirum Pharmaceuticals Inc. | MIRM | 3.96% |
 Celcuity Inc. | CELC | 3.85% |
 Alkermes PLC | ALKS | 3.5% |
 CG oncology Inc. | CGON | 3.42% |
 Spyre Therapeutics Inc. | SYRE | 3.42% |
 Apellis Pharmaceuticals Inc. | APLS | 3.13% |
 Xenon Pharmaceuticals Inc. | XENE | 2.9% |
 Apogee Therapeutics Inc. | APGE | 2.82% |
 Crinetics Pharmaceuticals Inc. | CRNX | 2.6% |
 Travere Therapeutics Inc. | TVTX | 2.46% |
 Dianthus Therapeutics Inc. | DNTH | 2.4% |
 Edgewise Therapeutics Inc. | EWTX | 2.37% |
 Viking Therapeutics Inc. | VKTX | 2.22% |
 ACADIA Pharmaceuticals Inc. | ACAD | 2.18% |
 Newamsterdam Pharma Co. NV | NAMS | 2.12% |
 Oruka Therapeutics Inc. | ORKA | 2.01% |
 Denali Therapeutics Inc. | DNLI | 1.93% |
 Structure Therapeutics Inc. | GPCR | 1.72% |
 Tarsus Pharmaceuticals Inc. | TARS | 1.64% |
 Disc Medicine Inc. | IRON | 1.56% |
 Vera Therapeutics Inc. | VERA | 1.56% |
 Ideaya Biosciences Inc. | IDYA | 1.5% |
 Sarepta Therapeutics Inc. | SRPT | 1.44% |
 Mineralys Therapeutics Inc. | MLYS | 1.42% |
 Zai Lab Ltd. | ZLAB | 1.4% |
 Relay Therapeutics Inc. | RLAY | 1.38% |
 Celldex Therapeutics Inc. | CLDX | 1.36% |
 Sionna Therapeutics Inc. | SION | 1.16% |
 Pharvaris NV | PHVS | 1.15% |
 Taysha Gene Therapies Inc. | TSHA | 1.14% |
 Stoke Therapeutics Inc. | STOK | 1.13% |
 Galapagos NV | GLPG | 1.13% |
 Vericel Corp. | VCEL | 1.11% |
 Tyra Biosciences Inc. | TYRA | 1.08% |
 Palvella Therapeutics Inc. | PVLA | 1.06% |
 Amylyx Pharmaceuticals Inc. | AMLX | 1.06% |
 Rapport Therapeutics Inc. | RAPP | 1.06% |
 Nuvation Bio Inc. | NUVB | 1.04% |
 Oculis Holding AG | OCS | 1.01% |
 Agios Pharmaceuticals Inc. | AGIO | 0.94% |
 Immunocore Holdings PLC | IMCR | 0.93% |
 Immatics NV | IMTX | 0.92% |
 Novavax Inc. | NVAX | 0.91% |
 Bicara Therapeutics Inc. | BCAX | 0.9% |
 MBX Biosciences Inc. | MBX | 0.86% |
 KalVista Pharmaceuticals Inc. | KALV | 0.81% |
 ArriVent Biopharma Inc. | AVBP | 0.78% |
 Corvus Pharmaceuticals Inc. | CRVS | 0.77% |
 Maze Therapeutics Inc. | MAZE | 0.76% |
 MoonLake Immunotherapeutics | MLTX | 0.76% |
 Olema Pharmaceuticals Inc. | OLMA | 0.71% |
 Zenas Biopharma Inc. | ZBIO | 0.67% |
 MannKind Corp. | MNKD | 0.65% |
 Geron Corp. | GERN | 0.6% |
 Xencor Inc. | XNCR | 0.57% |
 ARS Pharmaceuticals Inc. | SPRY | 0.55% |
 Design Therapeutics Inc. | DSGN | 0.54% |
 Theravance Biopharma Inc. | TBPH | 0.51% |
 Kura Oncology Inc. | KURA | 0.5% |
 Alto Neuroscience Inc. | ANRO | 0.45% |
 Aclaris Therapeutics Inc. | ACRS | 0.34% |
 Candel Therapeutics Inc. | CADL | 0.33% |
 Tectonic Therapeutic Inc. | TECX | 0.33% |
 REGENXBIO Inc. | RGNX | 0.31% |
 Neurogene Inc. | NGNE | 0.3% |
 Upstream Bio Inc. | UPB | 0.3% |
 Rigel Pharmaceuticals Inc. | RIGL | 0.29% |
 Fulgent Genetics Inc. | FLGT | 0.28% |
 Atea Pharmaceuticals Inc. | AVIR | 0.27% |
 Vanda Pharmaceuticals Inc. | VNDA | 0.26% |
 Altimmune Inc. | ALT | 0.25% |
 Zura Bio Ltd. | ZURA | 0.25% |
 Akebia Therapeutics Inc. | AKBA | 0.24% |
 Delcath Systems Inc. | DCTH | 0.23% |
 Compass Therapeutics Inc. | CMPX | 0.2% |
 Forte Biosciences Inc. | FBRX | 0.2% |
 Anavex Life Sciences Corp. | AVXL | 0.18% |
 Protara Therapeutics Inc. | TARA | 0.18% |
 Rezolute Inc. | RZLT | 0.18% |
 Arcturus Therapeutics Holdings Inc. | ARCT | 0.15% |
 Bicycle Therapeutics PLC | BCYC | 0.15% |
 Aardvark Therapeutics Inc. | AARD | 0.07% |
 Cash Equivalent | USD | 0% |
 Novo Nordisk A/S | Novo.Nordisk.A.S | 0% |
 Chinook Therapeutics Inc. | Chinook.Therapeutics.Inc. | 0% |
 AstraZeneca PLC | AstraZeneca.PLC | 0% |
| Sector | Weight |
|---|---|
|
Health care | 100.00% |
ALPS Medical Breakthroughs ETF (SBIO) share price today is $55.11.
Yes, Indians can buy shares of ALPS Medical Breakthroughs ETF (SBIO) on Vested. To buy SBIO from India, you can open a US Brokerage account by signing up on Vested. The account opening process is completely digital and secure, and takes 3-5 minutes to complete.
Yes, you can purchase fractional shares of ALPS Medical Breakthroughs ETF (SBIO) on Vested. You can start investing in ALPS Medical Breakthroughs ETF (SBIO) with a minimum investment of $1.
The 52-week high price of ALPS Medical Breakthroughs ETF (SBIO) is $57.77. The 52-week low price of ALPS Medical Breakthroughs ETF (SBIO) is $28.
The stock symbol (or ticker) of ALPS Medical Breakthroughs ETF is SBIO.
Yes, you can setup SIP in ALPS Medical Breakthroughs ETF shares. Follow the below steps to create the SIP:
Here is the historical performance of SBIO on the Vested app.
The expense ratio of ALPS Medical Breakthroughs ETF (SBIO) is 0.5%.
Link copied 
